comparemela.com

Latest Breaking News On - Cyclo therapeutics - Page 18 : comparemela.com

Cyclo Therapeutics (CYTH) Reports Publication of Data from Phase 2 Study of Trappsol Cyclo

Cyclo Therapeutics (CYTH) Reports Publication of Data from Phase 2 Study of Trappsol Cyclo
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
Caroline-hastings
Jenene-thomas
Company-trappsol
Nasdaq
Company-phase
Global-principal-investigator-for-the-company
Program-steering-committee
Cyclo-therapeutics-inc
Exchange-commission
Cyclo-therapeutics
Molecular-genetics

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

– Data published in official journal of Molecular Genetics and Metabolism Reports: Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion Trappsol® Cyclo™ was detected in the CSF Completers had an 88.9% improvement in at least two domains of the 17-Domain Niemann-Pick Type C1 Clinical Severity Scale (17D-NPC-CSS) Improvement in Scale Assessment and Rating of Ataxia (SARA) score for the mean score in 7 of 8 domains at Week 48 compared with baseline Demonstrated a favorable benefit-risk profile

United-states
Caroline-hastings
Company-phase
Global-principal-investigator-for-the-company
Program-steering-committee
Exchange-commission
Cyclo-therapeutics-inc
Company-trappsol
Nasdaq
Cyclo-therapeutics
Molecular-genetics
Global-principal-investigator

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Update

Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Rating) was the target of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 61,700 shares, an increase of 11.8% from the May 15th total of 55,200 shares. Based on an average daily volume of 137,900 shares, the […]

Markus-sieger
Renaissance-technologies
Cyclo-therapeutics-inc
Securities-exchange-commission
Maxim-group
Nasdaq
Cyclo-therapeutics
Get-rating
Director-markus-sieger
Exchange-commission
Scott-fine
Trappsol-cyclo

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Update

Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Rating) was the recipient of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 61,700 shares, a growth of 11.8% from the May 15th total of 55,200 shares. Based on an average trading volume of 137,900 shares, the […]

Markus-sieger
Renaissance-technologies
Maxim-group
Cyclo-therapeutics-inc
Securities-exchange-commission
Nasdaq
Cyclo-therapeutics
Get-rating
Director-markus-sieger
Exchange-commission
Scott-fine
Trappsol-cyclo

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Since the end of the third quarter, we made an initial $2.1 million investment in Cyclo Therapeutics, Inc. and have an agreement to increase our investment by $5 million NEWARK, N.J., June 13, 2023 . | June 13, 2023

Barbara-ryan
Rafael-holdings
Other-pharmaceuticals
Barer-institute
Cornerstone-pharmaceuticals
Cornerstone-pharmaceuticals-inc
Rafael-holdings-inc
Cyclo-therapeutics-inc
Nasdaq
Rafael-pharmaceuticals-inc
Cyclo-therapeutics
Bill-conkling

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.